26 April 2024
26 April 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
The company’s sales for Q1 2024 increased by 9% to $15.77bn.
The company's total revenue surged by 19% to $12.68bn in Q1 2024, driven by an 18% increase in product sales.
As the Biden Administration faces lawsuits from pharma companies, industry experts discuss the impact of the Inflation Reduction Act on R&D.
The developed medicines can be delivered to tissues beyond the liver, a current limitation in the field.
Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.
Multiply Labs said the technology could minimise human error and increase output.
Welcome to the first of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?” Transactions involving digital assets are becoming an increasing focus for pharmaceutical companies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
